Arena Pharmaceuticals (ARNA +4.3%) rallies with the help of a Sunday Bloomberg column discussing potential M&A interest in the drug developer, thanks to recent FDA approval of its Belviq weight-loss drug. Analysts speculate GlaxoSmithKline (currently divesting a diet pill line) or Japan's Eisai (the U.S. launch partner for Belviq) could make a bid. 25.3% of Arena's float was shorted as of June 15.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Fri, 4:22PM)
at Benzinga.com (Jan 14, 2015)
at Benzinga.com (Jan 13, 2015)
at Nasdaq.com (Jan 8, 2015)
at CNBC.com (Jan 7, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs